Exploring immunotherapy in colorectal cancer

Exploring immunotherapy in colorectal cancer

Abstract Chemotherapy combined with or without targeted therapy is the fundamental treatment for metastatic colorectal cancer (mCRC). Due to the adverse effects of chemotherapeutic drugs and the biological characteristics of the tumor cells, it is difficult to make breakthroughs in traditional strat...

Full description

Bibliographic Details
Main Authors:	Junyong Weng, Shanbao Li, Zhonglin Zhu, Qi Liu, Ruoxin Zhang, Yufei Yang, Xinxiang Li
Format:	Article
Language:	English
Published:	BMC 2022-07-01
Series:	Journal of Hematology & Oncology
Subjects:	Metastatic colorectal cancer Immune checkpoint blockade Immunotherapy Biomarkers Immune desert Microsatellite instability
Online Access:	https://doi.org/10.1186/s13045-022-01294-4

Similar Items

Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
by: Jiahao Zhu, et al.
Published: (2023-03-01)

The age of enlightenment in melanoma immunotherapy
by: Mark R. Albertini
Published: (2018-08-01)

Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
by: Pengfei Zhao, et al.
Published: (2019-05-01)

Emerging evidence of immunotherapy for colorectal cancer
by: Yuji Miyamoto, et al.
Published: (2023-03-01)

The Expression Patterns of Immune Checkpoint Molecules in Colorectal Cancer: An Analysis Based on Microsatellite Status
by: Sanghyun An, et al.
Published: (2024-03-01)

Identification of hub genes and potential molecular mechanisms in MSS/MSI classifier primary colorectal cancer based on multiple datasets
by: Xia Qiao, et al.
Published: (2024-07-01)

Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal Cancer: A Promising Individualized Treatment Strategy
by: Ying Yang, et al.
Published: (2023-04-01)

CTLA-4 blockade in the treatment of colorectal cancer with microsatellite instability
by: Diana Russo, et al.
Published: (2021-03-01)

Immune checkpoint inhibitors in colorectal cancer: limitation and challenges
by: Suying Yan, et al.
Published: (2024-06-01)

The trends and hotspots of immunotherapy for metastatic colorectal cancer from 2013 to 2022: A bibliometric and visual analysis
by: Yifan Gong, et al.
Published: (2024-12-01)

Immunotherapy regimens for metastatic colorectal carcinomas
by: Babar Bashir, et al.
Published: (2018-02-01)

Immunotherapy, Inflammation and Colorectal Cancer
by: Charles Robert Lichtenstern, et al.
Published: (2020-03-01)

Progress of Biomarkers to Predict Response to Immune Checkpoint Inhibitors in Microsatellite Stability Colorectal Cancer
by: WANG Zhiqiang, et al.
Published: (2023-02-01)

The next bastion to be conquered in immunotherapy: microsatellite stable colorectal cancer
by: Kai Ding, et al.
Published: (2023-12-01)

Role of DNA repair defects in predicting immunotherapy response
by: Jing Zhang, et al.
Published: (2020-06-01)

Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
by: Anne Hansen Ree, et al.
Published: (2024-12-01)

Attenuated Salmonella potentiate PD-L1 blockade immunotherapy in a preclinical model of colorectal cancer
by: Besan H. Al-Saafeen, et al.
Published: (2022-12-01)

A metal-organic nanoframework for efficient colorectal cancer immunotherapy by the cGAS-STING pathway activation and immune checkpoint blockade
by: Xiaodian Zhang, et al.
Published: (2024-09-01)

Pathological complete response after neoadjuvant immunotherapy combined with chemotherapy in pediatric rectal carcinoma: A case report
by: Xiaomeng Cao, et al.
Published: (2022-12-01)

Engineering nanoparticles to reprogram radiotherapy and immunotherapy: recent advances and future challenges
by: Jing Jin, et al.
Published: (2020-05-01)

Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report
by: Tamotsu Sagawa, et al.
Published: (2023-07-01)

Tumor microenvironment and immunotherapy of oral cancer
by: Chang Liu, et al.
Published: (2022-10-01)

Pancancer analysis of a potential gene mutation model in the prediction of immunotherapy outcomes
by: Lishan Yu, et al.
Published: (2022-08-01)

The current landscape of predictive and prognostic biomarkers for immune checkpoint blockade in ovarian cancer
by: Yufei Xu, et al.
Published: (2022-10-01)

The baseline hemoglobin level is a positive biomarker for immunotherapy response and can improve the predictability of tumor mutation burden for immunotherapy response in cancer
by: Yin He, et al.
Published: (2024-10-01)

Dendritic Cells and Their Role in Immunotherapy
by: Alycia Gardner, et al.
Published: (2020-05-01)

A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance
by: Ginette S. Santiago-Sánchez, et al.
Published: (2024-12-01)

Sintilimab plus bevacizumab, oxaliplatin and capecitabine as first-line therapy in RAS-mutant, microsatellite stable, unresectable metastatic colorectal cancer: an open-label, single-arm, phase II trialResearch in context
by: Xuefeng Fang, et al.
Published: (2023-08-01)

Cancer immunotherapies: advances and bottlenecks
by: Rui Rui, et al.
Published: (2023-08-01)

Prospects of immune checkpoint blockade and vaccine-based immunotherapy for glioblastoma
by: Tietze Stefanie, et al.
Published: (2021-04-01)

Improving the efficacy of combined radiotherapy and immunotherapy: focusing on the effects of radiosensitivity
by: Zhiru Gao, et al.
Published: (2023-05-01)

Efficacy and safety of sintilimab plus bevacizumab and CAPOX as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer
by: Yanrong Wang, et al.
Published: (2025-03-01)

Revolutionizing cancer immunotherapy: The dual role of clofazimine in enhancing efficacy and reducing toxicity
by: Yiran Zhu, et al.
Published: (2024-07-01)

Immunohistochemical scoring of LAG-3 in conjunction with CD8 in the tumor microenvironment predicts response to immunotherapy in hepatocellular carcinoma
by: Chun Chau Lawrence Cheung, et al.
Published: (2023-06-01)

PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma
by: Niklas Klümper, et al.
Published: (2023-12-01)

Colorectal Cancer Immunotherapy: State of the Art and Future Directions
by: Alyssa Mauri Cornista, et al.
Published: (2023-01-01)

KMT2C mutation as a predictor of immunotherapeutic efficacy in colorectal cancer
by: Chunhua Ni, et al.
Published: (2024-04-01)

PD-L2 act as an independent immune checkpoint in colorectal cancer beyond PD-L1
by: Lvyun Zhu, et al.
Published: (2024-12-01)

Evaluation of blood MSI burden dynamics to trace immune checkpoint inhibitor therapy efficacy through the course of treatment
by: Egor Veselovsky, et al.
Published: (2024-10-01)

Targeting STAT3 in Cancer Immunotherapy
by: Sailan Zou, et al.
Published: (2020-09-01)